Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05190042
Other study ID # 307-GIE-Suture
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 18, 2022
Est. completion date July 30, 2022

Study information

Verified date March 2024
Source Affiliated Hospital to Academy of Military Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The use of clips to completely clip mucosal defects after ESD/EMR can reduce postoperative adverse events, but the rate of incomplete mucosal defects closure is high. The continuous suture technique can completely close the mucosal defects by using surgical sutures and clips to suture the mucosal defects after ESD/EMR. In this study, a clinical randomized controlled study was conducted in our hospital. A total of 62 enrolled patients were divided into two groups, 31 patients were set as a treatment group using continuous suture technique to close post-EMR/ESD mucosal/submucosal defects, the rest patients were set as a control group using clips. The safety and effectiveness of continuous sutures and clips to clamp the post-EMR/ESD mucosal/submucosal defect were compared in the two groups. The complete mucosal/submucosa defects closure rates were the primary outcome.


Description:

Endoscopic submucosal resection (EMR) or submucosal dissection (ESD) for gastrointestinal lesions were used to treat early gastrointestinal cancer or large benign polyps, and their complete resection rates were high, which greatly reduce unnecessary surgical operations. However, after endoscopic resection of mucosal/submucosal lesions, large mucosal/submucosal defects may be created. These defects may cause more delayed postoperative adverse events (bleeding, perforation). The use of clips to completely seal the mucosal defect after gastrointestinal mucosal/submucosal lesion resection can significantly reduce postoperative adverse events, but the rate of incomplete mucosal defects closure is high. The surgical sutures combined with clips to close the mucosal defect after surgery significantly increased the complete closure rates of the post-EMR/ESD mucosal/submucosal defect. This study intends to further determine its safety and effectiveness through a clinical randomized controlled study, and standardize indications and contraindications. A total of 62 enrolled patients were allocated into two groups, 31 patients were set as a treatment group using continuous suture technique to close post-EMR/ESD mucosal/submucosal defects, the rest patients were set as a control group using clips. The safety and effectiveness of continuous sutures and clips to clamp the post-EMR/ESD mucosal/submucosal defect were compared in the two groups. The primary outcome was complete mucosal/submucosa defects closure rates. The secondary outcomes were the closure time, closure speed, and immediate bleeding during the operation as well as delayed bleeding, delayed perforation, and polyps syndrome after resection.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date July 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The indications for endoscopic resection were large (=20mm in diameter), nonpedunculated, benign, and early malignant mucosal or submucosal gastric or colorectal lesions. 2. Written informed consent Exclusion Criteria: 1. The tumor has spread to the muscularis layer, lymph nodes, or distal metastases; 2. Multiple lesions (=20mm in diameter) ; 3. Underlying bleeding disorder; 4. The platelet count less than 50×10^9/L; 5. Serious cardio-pulmonary, hepatic or renal disease; 6. Intolerance to endoscopy; 7. Other high-risk conditions or disease (such as massive ascites, etc.); 8. Pregnancy.

Study Design


Intervention

Device:
Cotinuous suture
Cotinuous suture using surgery thread
Clips
Hemostatic clips

Locations

Country Name City State
China The Fifth Medical Center of Chinese PLA General Hosptial Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Affiliated Hospital to Academy of Military Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The rates of complete closure of mucosal/submucosal defects When the clips were applied next to each other and there were no substantial submucosal areas in the closure line 1day
Secondary The duration time of closure The duration of closure was defined as the interval from insertion of the first clip until complete or incomplete closure 1 day
Secondary The closure speed The closure speed was defined as the resection area divided by 10x the duration of the ligation procedure (cm2 /10 minutes). 1day
Secondary Immediate bleeding Immediate bleeding refers to those episodes of hemorrhage that occurred during the procedure and lasted more than 30 seconds or required endoscopic treatment. 1 day
Secondary Delayed bleeding Delayed bleeding was defined as bleeding requiring emergency endoscopic hemostasis or transfusion or the presence of hemoglobin loss=2 g/dL after EMR/ESD 14 days
Secondary Delayed perforation Delayed perforation was defined as the presence of free air on abdominal CT or radiography after completion of the procedure in patients without perforation during EMR/ESD and no symptoms of peritoneal irritation after EMR/ESD 14 days
Secondary Post polypectomy syndrome Post polypectomy syndrome was defined by symptoms of pain, fever, leukocytosis, peritoneal tenderness, and guarding. 14 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Completed NCT05178095 - Artificial Intelligence in Colonic Polyp Detection N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Not yet recruiting NCT05552729 - Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors Phase 1/Phase 2
Recruiting NCT02871245 - Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery N/A
Not yet recruiting NCT02860429 - Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Phase 4
Completed NCT04694521 - Outcomes of Side-to-end Versus End-to-end Colorectal Anastomosis in Non-emergent Sigmoid and Rectal Cancers: Randomized Controlled Clinical Trial N/A
Completed NCT02454647 - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients N/A
Recruiting NCT02196935 - Los Angeles Prospective GI Biliary and EUS Series
Completed NCT00190801 - Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma Phase 2
Completed NCT00289445 - Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment) Phase 1/Phase 2
Completed NCT04010227 - Telephone Support for Advanced Gastrointestinal Cancer Patients and Caregivers N/A
Recruiting NCT03330964 - Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity N/A
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Recruiting NCT02672774 - Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers N/A
Completed NCT02444572 - Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® Phase 4